60,000 Shares in Ascendis Pharma A/S $ASND Bought by Integral Health Asset Management LLC

Integral Health Asset Management LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 60,000 shares of the biotechnology company’s stock, valued at approximately $11,929,000. Integral Health Asset Management LLC owned about 0.10% of Ascendis Pharma A/S as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ASND. Jones Financial Companies Lllp increased its stake in Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 83 shares in the last quarter. Quadrant Capital Group LLC purchased a new stake in Ascendis Pharma A/S during the third quarter valued at about $74,000. Farther Finance Advisors LLC lifted its stake in Ascendis Pharma A/S by 115.3% during the third quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 256 shares in the last quarter. Toth Financial Advisory Corp boosted its stake in Ascendis Pharma A/S by 33.7% in the 3rd quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 150 shares during the period. Finally, GAMMA Investing LLC grew its position in Ascendis Pharma A/S by 15.2% during the 3rd quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 97 shares in the last quarter.

Analysts Set New Price Targets

ASND has been the subject of several research analyst reports. Bank of America reissued a “buy” rating and issued a $262.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, March 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 21st. TD Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, January 7th. Barclays assumed coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 27th. They set an “overweight” rating and a $342.00 price target on the stock. Finally, Stifel Nicolaus set a $332.00 price target on shares of Ascendis Pharma A/S in a research note on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $289.88.

Ascendis Pharma A/S Stock Down 1.3%

Shares of Ascendis Pharma A/S stock opened at $225.98 on Friday. Ascendis Pharma A/S has a 12-month low of $124.06 and a 12-month high of $248.60. The stock has a 50 day moving average price of $224.24 and a two-hundred day moving average price of $211.10. The stock has a market capitalization of $14.01 billion, a P/E ratio of -51.36 and a beta of 0.43.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The firm had revenue of $290.38 million for the quarter, compared to analyst estimates of $285.35 million. Sell-side analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.